Using Proteomics To Advance Understanding of Alzheimer’s Disease
Fill out the form below and we'll send your colleague an invitation to the "Using Proteomics To Advance Understanding of Alzheimer’s Disease" event.
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
You’ll learn how mass spectrometry-based proteomics provides insights into brain changes and assists biomarker discovery in cerebrospinal fluid and plasma, and discover the potential of affinity-based proteomics for reliable biomarker identification. Our expert speaker will delve into intricate networks like proteostasis and the matrisome, highlighting their implications for therapeutic development.
- Gain insights into the landscape of AD brain changes using unbiased mass spectrometry-based proteomics
- Learn about biomarker discovery in AD cerebrospinal fluid and plasma through multi-platform proteomic analysis
- Understand the potential of affinity-based proteomics, including modified aptamer technology, in identifying reliable biomarkers for AD
- Explore the intricate networks associated with AD pathology and their implications for therapeutic development